Celgene has paid biotech startup Vividion $101m up front in a strategic partnership that includes an equity investment of undisclosed size.
US-based biotech developer Vividion Therapeutics secured $101m from pharmaceutical firm Celgene yesterday as part of a strategic collaboration agreement.
The money consists of equity funding and an upfront payment, though individual sizes of each were not disclosed.
Spun out from medical research organisation Scripps Research Institute in 2013, Vividion has developed a platform to assess drug candidates in native biological systems, rather than in an artificial environment which limits the scope of traditional drug discovery processes.
The company is looking…
